Other - Cuxabrain (Brand name: nootropil)

INDICATIONS

NOOTROPIL is indicated for patients suffering from myoclonus of cortical origin, irrespective of aetiology, and should be used in combination with other anti-myoclonic therapies.

INSTRUCTIONS

Adults :

The dosage regime shows important interindividual variability, requiring an individualised dose finding approach. A reasonable protocol would be to introduce piracetam at a dosage of 7.2 g/day, increasing by 4.8 g/day every 3 to 4 days up to a maximum of 20g/day, given in either 2 or 3 divided doses while keeping other antimyoclonic drugs unchanged at their optimal dosage. If possible, depending on clinical benefit, an attempt should be made to subsequently reduce the dosage of other antimyoclonic drugs.

DOSAGE

Take the medicine as prescribed by your doctor.

STORAGE

Store this medicine at room temperature in a tightly-closed container, away from heat and light.

MORE INFO:

 Active ingredient: Piracetam

SAFETY INFORMATION

NOOTROPIL (Piracetam) is contra-indicated in patients with severe renal impairment (renal creatinine clearance of less than 20 ml per minute), hepatic impairment and to those under 16 years of age. It is also contraindicated in patients with cerebral haemorrhage, Huntington's Chorea and in those with hypersensitivity to piracetam, other pyrrolidone derivatives or any of the excipients .

More Information


Nootropil should not be prescribed during pregnancy or when breastfeeding.

SIDE EFFECTS

The side effects reported in connection with Nootropil include nervousness, agitation, irritability, anxiety and sleep disturbances. The incidence of these during clinical trials was 5% or less and they were more often noted in the older patients taking more than 2.4 g daily. In the majority of cases a dose reduction sufficed to make these symptoms disappeared. Some patients may complain of fatigue or drowsiness. Gastro-intestinal problems such as nausea, vomiting, diarrhoea and stomachache have also been reported, but their Incidence during clinical trials was 2% or less. Other symptoms, such as vertigo, headaches, trembling and sexual stimulation have occasionally been reported.